Newer GLP-1 receptor agonists and obesity-diabetes

Brown, Emily, Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822 and Wilding, John P ORCID: 0000-0003-2839-8404
(2018) Newer GLP-1 receptor agonists and obesity-diabetes. PEPTIDES, 100. pp. 61-67.

[img] Text
Peptides-Newer GLP-1 receptor agonists and obesity-diabetes-Revision.docx - Author Accepted Manuscript

Download (490kB)


Obesity is a major risk factor for type 2 diabetes and may complicate type 1 diabetes. In parallel with the global epidemic of obesity, the incidence of type 2 diabetes is increasing exponentially. To reverse these alarming trends, weight loss becomes a major therapeutic priority in prevention and treatment of type 2 diabetes. Given that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycaemic control and cause weight loss, they are receiving increasing attention for the treatment of diabetes-obesity. This review discusses current and emerging therapeutic options with GLP-1 RAs and considers the next generation of novel peptide co-agonists with the potential for improved therapeutic outcomes in obesity and type 2 diabetes.

Item Type: Article
Uncontrolled Keywords: Diabetes, Obesity, GLP-1 agonists, Review
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 22 Apr 2021 12:45
Last Modified: 19 Jan 2023 01:14
DOI: 10.1016/j.peptides.2017.12.009
Related URLs: